Evidence map›Paper›PMID 27200103›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2016

A Fomitopsis pinicola Jeseng Formulation Has an Antiobesity Effect and Protects against Hepatic Steatosis in Mice with High-Fat Diet-Induced Obesity.

Hoe-Yune Jung, Yosep Ji, Na-Ri Kim, Do-Young Kim, Kyong-Tai Kim, Bo-Hwa Choi

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hoe-Yune JungPohang Center for Evaluation of Biomaterials, Pohang Technopark, Pohang 37668, Republic of Korea; Department of Life Science, Division of Integrative Biosciences and Biotechnology, POSTECH, Pohang 37673, Republic of Korea; R&D Center, NovMetaPharma Co., Ltd., Pohang 37668, Republic of Korea.
Yosep JiSchool of Life Science, Handong Global University, Pohang 37554, Republic of Korea.
Na-Ri KimPohang Center for Evaluation of Biomaterials, Pohang Technopark, Pohang 37668, Republic of Korea.
Do-Young KimPohang Center for Evaluation of Biomaterials, Pohang Technopark, Pohang 37668, Republic of Korea.
Kyong-Tai KimDepartment of Life Science, Division of Integrative Biosciences and Biotechnology, POSTECH, Pohang 37673, Republic of Korea.
Bo-Hwa ChoiPohang Center for Evaluation of Biomaterials, Pohang Technopark, Pohang 37668, Republic of Korea.
Pohang TechnoPark (South Korea) · KRHandong Global University · KRPohang University of Science and Technology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the antiobesity effect of an extract of the Fomitopsis pinicola Jeseng-containing formulation (FAVA), which is a combination of four natural components: Fomitopsis pinicola Jeseng; Acanthopanax senticosus; Viscum album coloratum; and Allium tuberosum. High-fat diet- (HFD-) fed male C57BL/6J mice were treated with FAVA (200 mg/kg/day) for 12 weeks to monitor the antiobesity effect and amelioration of nonalcoholic fatty liver diseases (NAFLD). Body and white adipose tissue (WAT) weights were reduced in FAVA-treated mice, and a histological examination showed an amelioration of fatty liver in FAVA-treated mice without decreasing food consumption. Additionally, FAVA reduced serum lipid profiles, leptin, and insulin levels compared with the HFD control group. The FAVA extract suppressed lipogenic mRNA expression levels from WAT concomitantly with the cholesterol biosynthesis level in the liver. These results demonstrate the inhibitory effects of FAVA on obesity and NAFLD in the diet-induced obese (DIO) mouse model. Therefore, FAVA may be an effective therapeutic candidate for treating obesity and fatty liver caused by a high-fat diet.

Identifiers

PMID27200103
PMCPMC4855004
OpenAlexW2336287897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.